Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2016-2026: Companies Looking to Replicate Wet AMD Drug Successes in Dry AMD, Glaucoma and Allergic, Inflammatory & Infective Ocular Conditions

Thursday, July 14, 2016 Drug News J E 4

NEW YORK, July 14, 2016 /PRNewswire/ -- Report DetailsWhat can be expected from the ophthalmic drugs market? Which companies are going to be most successful in the next 10 years? Which therapeutic areas are going to grow at the fastest rates? This visiongain report shows you potential revenues to 2026, assessing data, trends, opportunities and prospects in the market.Our 220-page report provides 160 tables, charts, and graphs. Discover the most successful companies, the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales across the whole ophthalmic drugs market. You will see financial results, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.Forecasts from 2016-2026 and other analyses show you commercial prospectsBesides revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT and Porter's Five Forces analysis) and commercial developments.In the report also you will find revenue forecasts to 2026 for the following submarkets in the ophthalmic drugs market:- Retinal Disorder Drugs- Allergic, Inflammatory & Infective Drugs- Glaucoma Drugs- Dry Eye Drugs- Other Ophthalmic DrugsThe report provides detailed profiles and revenue forecasts to 2026 for the following key companies operating within the ophthalmic drugs market:- Novartis- Regeneron- Allergan- Roche- Valeant- Santen- Bayer- Pfizer- Senju- AkornThe report also includes revenue forecasts to 2026 for the following ophthalmic drugs:- Eylea- Lucentis- Restasis- Lumigan and Ganfort- Travatan/Travatan Z and DuoTrav- Alphagan/Alphagan P and Combigan- Vigamox- Xalatan/Xalacom- Azopt- Jetrea- Hyalein- Cosopt- Tapros/Taflotan- Diquas- Cravit- Alesion- LotemaxLeading companies and potential for market growthNovartis (including subsidiary Alcon) will remain the leading ophthalmic company to 2026, our work forecasts. We predict strong revenue growth across the ophthalmic drugs market through to 2026. Advances in ocular drug delivery, treatments which address areas of unmet clinical need and the launch of several new therapies across all submarkets will drive sales to 2026.Our work analyses the key companies in the market. See visiongain's analysis of over 25 leading companies, including these:- Novartis- Regeneron- Allergan- Roche- Valeant- Santen- Bayer- Pfizer- Senju- AkornA company profile gives you the following information where available:- Discussion of a company's activities and outlook- Revenue forecasts to 2016 for ophthalmic drugs marketed by the company- Analysis of major products currently on the market- Acquisitions and strategic partnershipsDiscover capabilities, progress, and commercial prospects, helping you stay ahead.What issues will affect the ophthalmic drugs industry?Our new report discusses issues and events affecting the ophthalmic drugs market. You will find discussions, including qualitative analyses:- Highly diverse market needing strong knowledge of key therapeutic indications- Emerging therapies with the potential to reshape the marketYou will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.How the Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2016-2026 report helps youIn summary, our 220-page report gives you the following knowledge:- Revenue forecasts to 2026 for the 10 leading companies in the market – discover the industry's prospects for companies including: Novartis, Regeneron, Allergan, Roche, Valeant, Santen, Bayer, Pfizer, Senju and Akorn- Revenue forecasts to 2026 for each major submarket – discover prospects for leading ophthalmic drugs in the following areas: retinal disorder drugs, allergic, inflammatory & infective drugs, glaucoma drugs and dry eye drugs.- Revenue forecasts to 2026 for 17 leading drugs – discover prospects for leading ophthalmic drugs including: Eylea, Lucentis, Restasis, Lumigan and Ganfort, Travatan/Travatan Z and DuoTrav, Alphagan/Alphagan P and Combigan, Vigamox, Xalatan/Xalacom, Azopt, Jetrea, Hyalein, Cosopt, Tapros/Taflotan, Diquas, Cravit, Alesion and Lotemax.- Assessment of 21 emerging ophthalmic companies – analysis of products, revenue, mergers & acquisitions and leading pipeline drug candidates- Discussion of what stimulates and restrains companies and the market- Prospects for established firms and those seeking to enter the marketYou will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.Information found nowhere elseWith our survey you are less likely to fall behind in knowledge or miss opportunities. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.Visiongain's study is for everybody needing commercial analyses for the ophthalmic drugs market and leading companies. You will find data, trends and predictions. Please order our report now.Read the full report: Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________Contact Clare: US: (339)-368-6001Intl: +1 339-368-6001

To view the original version on PR Newswire, visit:

SOURCE Reportlinker



You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
US led Idiopathic Pulmonary Fibrosis Treatment Ind...
Blue Shield of California Files Lawsuit Against Ce...